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Changing TACTICS in intermediate HCC: 
TACE plus sorafenib
Pompilia Radu   ,1 Jean- François Dufour   1,2
Hepatocellular carcinoma (HCC) represents 
a serious health problem, mainly due to the 
high cancer- related mortality. Transarterial 
chemoembolisation (TACE) is currently 
used as the first- line treatment for 
intermediate- stage HCC (Barcelona Clinic 
Liver Cancer (BCLC) stage B), despite the 
fact that this stage comprises patients with a 
wide range of liver function, variable 
tumour number and size.1–4 In clinical prac-
tice, only 50%–60% of patients with BCLC 
stage B benefit from TACE, so TACE is 
usually repeated to achieve maximum 
tumour recession. The main factors that 
impact the effectiveness of TACE include 
the worsening of both the liver function and 
recurrence rate. The latter is the result of 
the angiogenic response triggered by TACE- 
induced hypoxia, which stimulates residual 
tumour growth.5 This has led to the concept 
that combining TACE with an antiangio-
genic treatment such as sorafenib will offer 
better tumour control.6 During the last 
decade, this hypothesis was tested in several 
trials, but the results were inconsistent.7–10 
According to a recent meta- analysis the 
combination of TACE plus sorafenib for 
unresectable HCC was superior in terms of 
time to progression but not in overall 
survival (OS).11
In Gut, a new trial combining TACE with 
sorafenib, the TACTICS trial, is published.12 
The authors report that in patients with 
BCLC stage B, the progression- free survival 
(PFS), which was 13 months with TACE 
alone, reached 25 months with the addi-
tion of sorafenib to TACE. Similarly, the 
time to untreatable (unTACEable) progres-
sion increased significantly from 21 to 
27 months. No significant differences in 
adverse events between the two treatment 
arms were observed. This trial stands out 
for being clearly positive with longer time 
to reach endpoints than those in previous 
trials (table 1).
Several aspects of the TACTICS 
trial have to be discussed. This trial 
used novel TACE progression criteria, 
according to which PFS was defined as 
the time to either unTACEable progres-
sion or death. Currently, the most 
commonly used evaluation radiological 
criteria of response to TACE are based 
on the measurement either of the tumour 
as a whole (Response Evaluation Criteria 
in Solid Tumors V.1.1) or of its viable 
portion (modified Response Evaluation 
Criteria in Solid Tumors), without taking 
into consideration the patterns of HCC 
progression.13 In the TACTICS trial, the 
authors evaluated the treatment based 
on the Response Evaluation Criteria in 
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Cancer of the Liver (RECICL), according 
to which new intrahepatic lesions were 
no longer considered as progressive 
disease (PD). The PFS was defined as the 
time from randomisation to PD or death 
from any cause, and they define progres-
sion as untreatable (UnTACEable) 
progression, caused by the inability of a 
patient to further receive or benefit from 
TACE for reasons that included intrahe-
patic tumour progression (25% increase 
vs baseline) according to RECICL, 
the detection of extrahepatic spread, 
vascular invasion or transient deteriora-
tion of liver function to Child- Pugh C 
after TACE.
The timing of sorafenib adminis-
tration relative to TACE is important 
and differs among various studies. 
Several approaches have been tested 
for the timing of sorafenib initiation: 
(1) sequential administration, (2) the 
interrupted administration and (3) 
the continuous administration.14 The 
sequential approach involves treating 
patients with TACE, then initiating the 
sorafenib treatment (as an adjuvant 
therapy) once the TACE sessions have 
been completed.7 8 The interrupted 
approach involves placing patients on 
treatment with sorafenib between the 
TACE sessions and pausing sorafenib 
during TACE to avoid possible adverse 
events.9 10 In the continuous approach, 
patients are prescribed sorafenib without 
interruption before, during and after 
TACE. Although the first two approaches 
might be superior in reducing complica-
tions, the third approach has the benefit 
of potentially eliminating the angiogenic 
response after TACE- induced hypoxia 
and may therefore prevent tumour 
growth after TACE.15 The feasibility of 
this approach was demonstrated in an 
initial phase I trial that assessed sorafenib 
given continuously and that began 7 
days before TACE.16 In the TACTICS 
trial, patients included in the TACE plus 
sorafenib arm started sorafenib 2–3 weeks 
before TACE, at a dose of 400 mg once 
daily. This approach aimed to normalise 
the tumour vasculature, improve TACE 
effectiveness and suppress the cascade of 
proangiogenetic signalling pathways trig-
gered by TACE- induced hypoxia. In the 
TACTICS trial, TACE was administered 
‘on demand’ at the growth of the viable 
lesions, whereas in the phase 2SPACE 
trial, the TACE sessions were scheduled.9
The population enrolled in the TACTICS 
trial differs significantly from the patient 
population enrolled in previous trials 
combining TACE with sorafenib. In the 
TACTICS trial, 80% of patients were clas-
sified as having Child- Pugh A5 compared 
with 60%–68% in previous trials.7–10 Not 
surprisingly, patients with a less advanced 
Child- Pugh stage tend to have a longer OS 
when treated with sorafenib.15 Another 
possible difference in the patient population 
is the percentage of non- cirrhotic patients. 
In previous trials, the cohorts comprised 
up to 80% of cirrhotic patients, while this 
proportion was not stated in the TACTICS 
trial.
These specificities in the TACTICS 
trial design resulted in a longer sorafenib 
treatment length (38 weeks) compared 
Table 1 TACE plus sorafenib trials for BCLC stage B
Authors Kudo et al7 Park et al8 Lencioni et al9 Meyer et al10
Kudo et al12
Trial Ph3 post- TACE Ph2 TACE and sorafenib Ph2 SPACE Ph3 TACE-2 Ph2 TACTICS
Population randomised to sorafenib+TACE 196 patients, Japan, 
and 33 patients, South 
Korea
50 patients, South 
Korea
154 of which 59 
were from Asia (not 
including Japan)
157 patients, UK 80 patients, Japan
Cirrhosis, yes 312 (69.4%) NA 139 (90.3%) 129 (82%) NA
Child Pugh A5, n % NA NA 98 (63.6%) 106 (68%) 64 (80.0%)
Tumour burden ≤7 cm
≤10 lesions
BCLC stages B and C ≤7 cm
≤10 tumours
Unresectable, 
multinodular not 
amenable to resection or 
transplantation
≤10 cm
≤10 tumours
Progression criteria RECICL 2004 mRECIST mRECIST RECIST 1.1 UnTACEable progression/
TACE failure
A new lesion was not 
considered progressive 
disease.
Overall survival (months) Combined treatment 29.7 NA NR 20.7 NA
TACE alone NA NA NR 19.6 NA
PFS (months) Combined treatment NA 7.1 NA 7.8 25.2
TACE alone arm NA NA NA 7.7 13.5
TTP (months) Combined treatment 5.4 7.1 5.6 10.7 26.7
TACE alone 3.7 NA 5.5 10.5 16.4
TTUP (months) Combined treatment NA NA 3.1 NA 26.7
TACE alone NA NA 7.3 NA 20.6
Median daily sorafenib dose /day (mg) 386 600 566 660 355.2
The timing of pre- TACE/post- TACE sorafenib Sorafenib was given 
1–3 months after TACE 
until progression.
Sorafenib was given 
3 days after TACE and 
was administered for 
up to 24 weeks.
Sorafenib was started 
3–7 days before DEB- 
TACE, continuously 
until progression.
Sorafenib was started 
2–5 weeks prior to DEB- 
TACE continuously until 
progression.
Sorafenib was started 2–3 
weeks prior to first TACE, 
discontinued for 2 days 
before and 2 days after each 
TACE session.
TACE type and approach c TACE on demand c TACE on demand DEB- TACE scheduled DEB- TACE on demand c TACE on demand
Median durations of 
treatment
Combined treatment arm 
(weeks on Sorafenib)
17 5.1 21 3.9 38.7
TACE alone arm (weeks) 20 NA 27 5.3 NA
BCLC, Barcelona Clinic Liver Cancer; DEB- TACE, transcatheter arterial embolisation with doxorubicin- eluting beads; mRECIST, modified Response Evaluation Criteria in Solid Tumors; NA, not 
available; NR, not reached; PFS, progression- free survival; RECICL, Response Evaluation Criteria in Cancer of the Liver; RECIST V.1.1, Response Evaluation Criteria in Solid Tumors V.1.1; c TACE, 
conventional transcatheter arterial embolisation; TACE, transcatheter arterial embolisation; TTP, time to progression; TTUP, time to unTACEable progression.
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with previous trials (17–21 weeks). As 
BCLC stage B comprises a heterogeneous 
patient population, careful patient selec-
tion is essential. In this setting, several 
questions arise: (1) What is the benefit 
of adding sorafenib to TACE not only in 
terms of disease control but also in terms 
of quality of life and costs? (2) Which 
patients would benefit the most from the 
combination TACE and sorafenib (Asian/
non- Asian, cirrhotic/non cirrhotic)? (3) 
Which criteria are the most appropriate 
for evaluating therapeutic response? The 
answers to these questions are crucial 
in order to define the target population 
and to design the optimal protocol. The 
study by Kudo et al highlights the need 
to optimise treatment for patients with 
BCLC stage B.12 In order to achieve this, 
redefining the criteria for both patient 
selection and treatment evaluation may 
be required. Until new trials for BCLC 
stage B confirm the results obtained by 
Kudo et al, it remains a matter of debate 
whether the combination of TACE plus 
sorafenib is a suitable choice of treat-
ment for all patients with intermediate 
HCC or whether it should be reserved 
only for a specific group. Future studies 
that compare TACE plus sorafenib versus 
sorafenib alone in BCLC stage B may 
further improve our understanding of 
the real benefit of adding sorafenib to 
TACE.
Twitter Jean- François Dufour @dufour_jf
Contributors PR and J- FD wrote together this 
commentary.
Funding The authors have not declared a specific 
grant for this research from any funding agency in the 
public, commercial or not- for- profit sectors.
Competing interests J- FD: advisory committees: 
Bayer, BMS, Falk, Genfit, Genkyotex, Gilead Science, 
HepaRegenix, Intercept, Eli Lilly, Merck, Novartis; 
Speaking and teaching: Bayer, Bristol- Myers Squibb, 
Intercept, Genfit, Gilead Science and Novartis.
Patient and public involvement 
statement Patients and/or the public were not 
involved in the design, or conduct, or reporting, or 
dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Commissioned; 
internally peer reviewed.
Open access This is an open access article distributed 
in accordance with the Creative Commons Attribution 
Non Commercial (CC BY- NC 4.0) license, which permits 
others to distribute, remix, adapt, build upon this work 
non- commercially, and license their derivative works on 
different terms, provided the original work is properly 
cited, appropriate credit is given, any changes made 
indicated, and the use is non- commercial. See: http:// 
creativecommons. org/ licenses/ by- nc/ 4. 0/.
© Author(s) (or their employer(s)) 2020. Re- use 
permitted under CC BY- NC. No commercial re- use. See 
rights and permissions. Published by BMJ.
To cite Radu P, Dufour J- F. Gut 2020;69:1374–1376.
Received 16 January 2020
Revised 24 February 2020
Accepted 24 February 2020
Published Online First 13 March 2020
 ► http:// dx. doi. org/ 10. 1136/ gutjnl- 2019- 318934
Gut 2020;69:1374–1376.
doi:10.1136/gutjnl-2020-320692
ORCID iDs
Pompilia Radu http:// orcid. org/ 0000- 0001- 7208- 1477
Jean- François Dufour http:// orcid. org/ 0000- 0002- 8062- 
1346
RefeRences
 1 Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, 
staging, and management of hepatocellular 
carcinoma: 2018 practice guidance by the American 
association for the study of liver diseases. Hepatology 
2018;68:723–50.
 2 Omata M, Cheng A- L, Kokudo N, et al. Asia- Pacific 
clinical practice guidelines on the management of 
hepatocellular carcinoma: a 2017 update. Hepatol Int 
2017;11:317–70.
 3 Korean Liver Cancer Association, National Cancer 
Center. 2018 Korean liver cancer Association- National 
cancer center Korea practice guidelines for the 
management of hepatocellular carcinoma. Gut Liver 
2019;13:227–99.
 4 Bolondi L, Burroughs A, Dufour J- F, et al. Heterogeneity 
of patients with intermediate (BCLC B) hepatocellular 
carcinoma: proposal for a subclassification to facilitate 
treatment decisions. Semin Liver Dis 2012;32:348–59.
 5 Lencioni R. Loco- Regional treatment of hepatocellular 
carcinoma. Hepatology 2010;52:762–73.
 6 Dufour J- F, Johnson P. Liver cancer: from molecular 
pathogenesis to new therapies: summary of the EASL 
single topic conference. J Hepatol 2010;52:296–304.
 7 Kudo M, Imanaka K, Chida N, et al. Phase III study 
of sorafenib after transarterial chemoembolisation 
in Japanese and Korean patients with unresectable 
hepatocellular carcinoma. Eur J Cancer 
2011;47:2117–27.
 8 Park J- W, Koh YH, Kim HB, et al. Phase II study of 
concurrent transarterial chemoembolization and 
sorafenib in patients with unresectable hepatocellular 
carcinoma. J Hepatol 2012;56:1336–42.
 9 Lencioni R, Llovet JM, Han G, et al. Sorafenib or 
placebo plus TACE with doxorubicin- eluting beads 
for intermediate stage HCC: the space trial. J Hepatol 
2016;64:1090–8.
 10 Meyer T, Fox R, Ma YT, et al. Sorafenib in 
combination with transarterial chemoembolisation in 
patients with unresectable hepatocellular carcinoma 
(TACE 2): a randomised placebo- controlled, double- 
blind, phase 3 trial. Lancet Gastroenterol Hepatol 
2017;2:565–75.
 11 Li L, Zhao W, Wang M, et al. Transarterial 
chemoembolization plus sorafenib for the 
management of unresectable hepatocellular 
carcinoma: a systematic review and meta- analysis. 
BMC Gastroenterol 2018;18:138.
 12 Kudo M, Ueshima K, Ikeda M, et al. Randomised, 
multicentre prospective trial of transarterial 
chemoembolisation (TACE) plus sorafenib as compared 
with TACE alone in patients with hepatocellular 
carcinoma: TACTICS trial 2019.
 13 Tovoli F, Renzulli M, Granito A, et al. Radiologic criteria 
of response to systemic treatments for hepatocellular 
carcinoma. Hepat Oncol 2017;4:129–37.
 14 Strebel BM, Dufour J- F. Combined approach to 
hepatocellular carcinoma: a new treatment concept 
for nonresectable disease. Expert Rev Anticancer Ther 
2008;8:1743–9.
 15 Ziogas IA, Tsoulfas G. Evolving role of sorafenib in the 
management of hepatocellular carcinoma. World J Clin 
Oncol 2017;8:203–13.
 16 Dufour J- F, Hoppe H, Heim MH, et al. Continuous 
administration of sorafenib in combination with 
transarterial chemoembolization in patients with 
hepatocellular carcinoma: results of a phase I study. 
Oncologist 2010;15:1198–204.
 on S
eptem
ber 10, 2020 at U
niversitaetsbibliothek B
ern. P
rotected by copyright.
http://gut.bm
j.com
/
G
ut: first published as 10.1136/gutjnl-2020-320692 on 13 M
arch 2020. D
ow
nloaded from
 
